All News
Belimumab in Lupus Nephritis
Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.
Read Article
Orbitofrontal Cortex Implants to Assess Chronic Pain
Nature Neuroscience reports a novel approach to assessing chronic neuropathic pain - intracranial electrodes in the anterior cingulate cortex and orbitofrontal cortex (OFC) to map chronic pain signaling.
Read Article
UK Biobank cohort study (n=361,952) assessed BMI effects on rheumatic Dz risk. Higher BMI incr odds of RA (IRR=1.52), OA (IRR=1.49), PsA (IRR=1.80), gout (1.73), SpA(1.34); more pronounced in women for both gout and psoriatic arthropathy https://t.co/eLeeShSSv1 https://t.co/IjWF2EPqOR
Links:
Dr. John Cush RheumNow ( View Tweet)
PREVENT study looked at Xray progression in 438 nr-axSpA pts given PBO or secukinumab. At baseline there was little SI damage & at 2 yrs no SI progression (− 0.04 mSASSS) or spinal inflammation in both groups. https://t.co/3EgnK2rWgb https://t.co/z5umUhpViF
Links:
Dr. John Cush RheumNow ( View Tweet)
MRI study of SI jts in axSpA 196 pts shows w/ increasing bone marrow edema of SI, SI damage is likely. BME each quadrant incr odds: sclerosis (OR:1.9), erosions (1.9). BME lead to 5 yr SIJ damage if fluctuating (OR:5.6) or persistent (OR:7.5) https://t.co/Dkbcij5Uhv https://t.co/x83kErVb1E
Links:
Dr. John Cush RheumNow ( View Tweet)
A claims cohort comparison of #RA pts with H.zoster (n 1 866 ) and pts without HZ (38,846). RA+/HZ+ pts had significantly greater Hospitalizations, emergency visits (esp <30d post HZ Dx; adj IRR hosp=3.4; ED=3.7) and higher Total HC costs https://t.co/89GLUK93dO https://t.co/9jweduoBHw
Links:
Dr. John Cush RheumNow ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for:
-KOL perspective videos
-Clinical Trial Highlights
-Daily Faculty Recaps
-Live Streaming
and more! https://t.co/9uKnDTynfk
Dr. John Cush RheumNow ( View Tweet)
Join us for the final Tuesday Night Rheumatology of May.
This webinar will feature highlights from these lectures followed by live audience Q & A:
Methotrexate Use: 50 Yr. Perspective
Myths vs Reality in RA
Biosimilars - Back on the Agenda
https://t.co/0OenWkXarV https://t.co/yUHwslkZ9o
Links:
Dr. John Cush RheumNow ( View Tweet)
3-4-5 Rule
Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on https://t.co/V10S4oVFsv
https://t.co/4iQERIh5Zl https://t.co/bwSk9L7ucC
Dr. John Cush RheumNow ( View Tweet)
⚠️Beware not all bone marrow oedema =#AxSpA on MRI !
Signal seen in 17% volunteers at SIJs
@DrPoddubnyy
#RNL2023 https://t.co/xTKuSRXK72 https://t.co/c09QjSkJBP
Links:
Dr. John Cush RheumNow ( View Tweet)
FRAX Tool is Suboptimal in Predicting Osteoporosis Fracture Risk in Younger Post-menopausal Women
https://t.co/8tc51AJ14n https://t.co/lhF7iwl0N3
Links:
Dr. John Cush RheumNow ( View Tweet)
With all the new adalimumab biosimilars happening in 2023, where's the pen? Now the FDA has approved an ADA biosimilar, Cyltezo, Autoinjector Pen! https://t.co/TgsA46xGsv https://t.co/rXcRcp7tDX
Links:
Dr. John Cush RheumNow ( View Tweet)
Dennis Poddubnyy #RNL2023
MRI sequences for axSpA:
Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression
Semi-axial- T2 STIR
@RheumNow https://t.co/aidLu7GcQH https://t.co/YOrboYl6pW
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: GPA Treatment Choices
https://t.co/9v6C5nOLqu https://t.co/1E347ulsvR
Links:
Dr. John Cush RheumNow ( View Tweet)
Colchicine does not work in Hand OA. Danish trial of 100 HOA pts (age 71 yrs) given placebo or COL 0.5 mg bid x 12wk. Finger pain improved –13·9 mm w/ colchicine vs –13·5 mm w/ PBO (NS). More adverse events w/ Colchicine (72% vs 44%) https://t.co/042BQcAFWf https://t.co/EldLmjVisD
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Deodhar reminds us of his "3,4,5 rule" for diagnosing AS.
*Erosions in 3 or more SIJ quadrants
*BME in 4 or more SIJ quadrants
*Fat lesions in 5 of more SIJ quadrants
#RNL2023 @RheumNow https://t.co/T9iWLcNL8b https://t.co/BskCNz9Klj
Links:
Dr. John Cush RheumNow ( View Tweet)
Peresolimab's Potential in Rheumatoid Arthritis
Peresolimab is a humanized IgG1 monoclonal antibody that acts as a PD-1 agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active RA.
https://t.co/tBAC2vO31f https://t.co/pAknsSnnNT
Links:
Dr. John Cush RheumNow ( View Tweet)
U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults based on induction studies, U-EXCEED, U-EXCEL,& U-ENDURE maintenance study. This is 7th FDA approval for RINVOQ https://t.co/JFyiETe43S https://t.co/zGJKZ3l0d4
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us for the final Tuesday Night Rheumatology of May.
This webinar will feature highlights from these lectures followed by live audience Q & A:
Methotrexate Use: 50 Yr. Perspective
Myths vs Reality in RA
Biosimilars - Back on the Agenda
https://t.co/cqFNCRlGym https://t.co/fNS6cGBuDB
Links:
Dr. John Cush RheumNow ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for:
-KOL perspective videos
-Clinical Trial Highlights
-Daily Faculty Recaps
-Live Streaming
and more! https://t.co/uR4ZwnPGiF
Dr. John Cush RheumNow ( View Tweet)